science_technology_and_other_research_and_development · DOD-AMRAA
DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Defense Health Agency Contracting Activity - DHACA · HT942526DMDRPCTRA
Total Program Funding
$8.5M
Expected Awards
6
Deadline
September 18, 2026
GRANTQUICK SUMMARYPlain-English Overview
DoD's Duchenne Muscular Dystrophy Research Program Clinical/Translational Research Award funds 6 grants ($8.46M total, ~$1.4M each) for research that moves DMD treatments from lab toward clinical application. Must involve human subjects or be directly translatable to clinical use. This is the bridge between basic science and clinical trials — biomarker validation, natural history studies, or therapeutic development at the preclinical/early clinical stage.
Who Should Apply
Researchers at academic medical centers with DMD clinical/translational research programs. Must have access to DMD patients or registries and propose research with clear clinical applications.
Who Should NOT Apply
Basic science researchers without translational plans, clinical trialists (separate mechanism), or researchers without DMD-specific expertise.
Key Requirements (Plain English)
- •Must be clinical or translational DMD research
- •Must have clear pathway toward clinical application
- •6 awards totaling $8.46M (~$1.4M each)
- •Must involve human subjects or be directly translatable
- •Unrestricted eligibility
- •No cost-sharing required
💡 GrantQuick Tip
DMD is a devastating disease with an engaged patient community and advocacy groups (Parent Project Muscular Dystrophy). DoD funds DMD research specifically because of military families affected by it. Strong applications show: this is my therapeutic/biomarker/technology, here's my preclinical data, here's exactly how this grant moves it toward patients. Include DMD patient advocacy organizations in your application — they often provide letters of support and patient access.
Competitiveness: Moderate-high — 6 awards in a dedicated but small research community. The DMD field is highly collaborative and competitive simultaneously.
What This Grant Funds
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.
Distinctive Features: The FY26 CTRA offers two funding levels:
• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.
• Funding Level 2 to support larger, more complex preclinical and/or clinical research.
The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:
• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.
• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.
Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed.
Attachments
Who Can Apply
Eligible Applicant Types
Funding Details
- Total Program Funding
- $8.5M
- Expected Number of Awards
- 6
- Cost Sharing Required?
- No
- Funding Instrument
- grant
Key Dates
Agency Contact
eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
help@eBRAP.orgReady to apply?
View the full NOFO and submit your application on Grants.gov